RADNOR, Pa., May 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period"). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282- DDP-AJR was filed i ...

GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.While investors closely watch year-over-year changes in headline numbers -- revenue and earni ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Whitney Notaro - VP, IR Scott Wagner - Interim CEO Karsten Voermann - CFO Conference Call Participants Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Stephanie Davis - Barclays Daniel Grosslight - Citi Lisa Gill - JP Morgan Charles Rhyee - TD Cowen Stan Bernstein - Wells Fargo Securities Scott Schoenhaus - KeyBanc Sean Dodge - RBC Capital Markets John Ransom - RJF John Park ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 ________________________ ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.08, delivering no surprise.Over the last four quarters, the company ha ...

Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2024 RESULTS SANTA MONICA, Calif. -- (May 9, 2024) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights • Revenue1 and Adjusted Revenue1 of $197.9 million • Net loss of $1.0 million; Net loss margin of 0.5% • Adjusted Net Income1 of $32.6 million; Adjusted Net Income Margin1 ...

GoodRx Holdings Inc (NASDAQ:GDRX) stock is up 1.9% to trade at $6.87 this morning, after Keybanc upgraded the digital healthcare service to "overweight" from "sector weight," while setting a price target of $9. The analyst in coverage cited the potential for strong subscriber growth, as well as a positive shift in the company's monthly active users (MAUs). GoodRx  jumped nearly 4% premarket, but broad market headwinds are capping gains. The stock has support at its 80-day moving average, which has propped u ...

GoodRx Holdings, Inc. (GDRX) closed the last trading session at $6.77, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.74 indicates a 29.1% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $2.19. While the lowest estimate of $5 indicates a 26.1% decline from the current price level, the most optimistic analyst exp ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx of their decision to resign from the Company’s Board of Directors, effective March 14, 2024 and March 22, 2024, respectively. “I’m encouraged by the progress the team is making and happy to see the hard work start showin ...

GoodRx Holdings, Inc. (GDRX) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate re ...